GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

The purpose of this study is to explore the efficacy and safety of neoadjuvant GP chemotherapy plus adebrelimab versus neoadjuvant GP chemotherapy in treating high-risk locoregionally advanced nasopharyngeal carcinoma patients.

Trial Details

NCT ID
NCT06455410
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • GP
  • Adebrelimab
  • concurrent chemoradiotherapy (CCRT)
Locations (sample)
  • Foshan, Guangdong, China|23.02677,113.13148
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Patients must be informed of the investigational nature of this study and give written informed consent.
  • Age ≥ 18 years and ≤65 years, men or non-pregnant women.
  • Patients with histologically confirmed Nonkeratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, WHO II or III).
  • Tumor staged as T4N0-1M0 or T1-4N2-3M0 (AJCC 8th).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →